Bipolar depression

This study tests whether the drug lumateperone can improve mood and reduce inflammation in adults with bipolar depression who also have obesity. Over about six weeks, participants take lumateperone daily and undergo mood assessments and an MRI to estimate brain age. The goal is t…

This study compares dapagliflozin and metformin for managing weight gain caused by antipsychotic medications. About 110 adults aged 16 and older will take one of the drugs plus lifestyle advice for 26 weeks. The goal is to see which drug works better and is safer for weight contr…

This study tests a smartphone app called Senyo Health for people with bipolar disorder who also struggle with alcohol or drug use. The app offers therapy, rewards for healthy behaviors, and weekly check-ins with a care manager. The goal is to see if the app is easy to use and hel…

This pilot study tests whether MyFILM, a 9-week group program using clips from the movie Inside Out, is feasible and acceptable for children aged 9-12 with mood or anxiety concerns. Participants attend weekly sessions to learn social-emotional skills and coping strategies. The st…

This study tests whether a non-invasive brain stimulation technique called rTMS can improve depression in people with bipolar disorder. Researchers use brain scans to create a personalized map for each participant, targeting the exact brain circuits involved in mood shifts. Parti…

This Phase 3 trial tests whether pramipexole, a dopamine-boosting drug, can ease anhedonia (loss of pleasure) in people with bipolar depression. 126 participants will receive either pramipexole or a placebo alongside their usual mood stabilizer for 6 weeks. The study aims to impr…

This study compares two drugs, lumateperone and cariprazine, when added to a mood stabilizer for people with bipolar I depression. Researchers will track changes in depression symptoms over 8 weeks using standard rating scales. The goal is to see which drug works better and has f…

This study tests an oral ketamine capsule (KET-AD) designed to be abuse-deterrent in adults with treatment-resistant bipolar depression. About 160 participants will receive either KET-AD or a placebo, taken three times a week for up to 7 weeks, alongside their usual treatment. Th…

This study tests whether baricitinib, an anti-inflammatory drug, can improve depression and cognitive symptoms in 30 male former football players aged 40-55 with at least 10 years of play. Participants take the drug every other week for 6 weeks, and researchers use brain scans an…

This study tests whether two anti-inflammatory medications, celecoxib or minocycline, can reduce depression symptoms in adults with major depressive disorder or bipolar depression. About 42 participants will take one of the drugs for 8 weeks and have their depression levels measu…

This study tests a wearable light device (Vielight RX Gamma) that shines light on the brain to see if it safely eases bipolar depression symptoms. Forty people with bipolar disorder will either get the active device or a sham (inactive) one, using it in the clinic 5 days a week f…

This study tests whether empagliflozin, a drug used for diabetes, can help reduce depression in people with bipolar disorder who also have insulin resistance. Twenty adults with bipolar depression will take the drug for 12 weeks alongside their usual treatment. The goal is to see…

This study tests whether a single 'Braining' group exercise session can quickly reduce anxiety in people receiving psychiatric care. Thirty participants will rate their anxiety before and after the session. The goal is to see if exercise can be a fast-acting tool to ease symptoms…

This study will test a digital tool called AI-COA® to see how well it measures the severity of depression and anxiety compared to standard clinician ratings. About 150 adults in the U.S. who are starting a new treatment for depression or anxiety will use the tool over 12 weeks. T…

This study will follow 2,000 adults with major depressive disorder or bipolar disorder to understand why some people get better with treatment and others do not. Researchers will collect information on symptoms, thinking abilities, genetics, metabolism, proteins, and immune marke…

This study aims to better understand why young people (ages 18-25) with mood disorders may be at risk for suicide. Researchers will collect clinical, brain imaging, genetic, and microbiome data from 180 participants to identify risk factors. They will also test whether a non-inva…